Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial (2023)

First Author: Compagnucci A

Attributed to: Paediatric and adolescent infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2023.102025

PubMed Identifier: 37304494

Publication URI: http://europepmc.org/abstract/MED/37304494

Type: Journal Article/Review

Parent Publication: eClinicalMedicine